Abstract PORTEC-4a was the first to incorporate molecular-integrated profile-guided adjuvant treatment in early-stage high-intermediate-risk endometrial cancer (EC), demonstrating non-inferiority. Here, adverse events (AE), health-related quality of life (HRQoL) and sexual health are reported. 564 patients were randomised to molecular-based adjuvant treatment (n = 367) or standard vaginal brachytherapy (VBT, n = 197).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Marlies E.
Contact Marlies E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack